Cyclerion Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.9M |
| Research and development | $959,000 | $286,000 | $1.5M | $6.0M | $37.6M |
| Operating expenses | $7.0M | $5.6M | $13.0M | $18.8M | $59.1M |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M |
| Pretax income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M |
| Balance Sheet | |||||
| Cash and equivalents | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M |
| Current assets | $4.6M | $4.2M | $8.0M | $14.8M | $55.5M |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M |
| Current liabilities | $900,000 | $725,000 | $2.1M | $7.6M | $11.1M |
| Stockholders' equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M |
| Depreciation and amortization | — | — | $0 | $65,000 | $472,000 |
| Stock-based compensation | $441,000 | $625,000 | $1.1M | $6.3M | $9.6M |
| Capital expenditure | — | — | — | $0 | $7,000 |
| Free cash flow | — | — | — | -$40.6M | -$36.5M |
| Impairments | — | $0 | $3.3M | $0 | — |
Shares outstanding 4.3M · Free float 27.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.